Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) dropped 0.8% on Friday . The company traded as low as $17.16 and last traded at $17.33, with a volume of 66,440 shares traded. The stock had previously closed at $17.47.

BLCM has been the topic of a number of research reports. Jefferies Group restated a “buy” rating on shares of Bellicum Pharmacueticals in a report on Tuesday, August 23rd. Piper Jaffray Cos. reiterated a “buy” rating on shares of Bellicum Pharmacueticals in a report on Saturday, July 9th. SunTrust Banks Inc. assumed coverage on Bellicum Pharmacueticals in a report on Thursday, June 2nd. They set a “buy” rating and a $20.00 target price on the stock. Citigroup Inc. upgraded Bellicum Pharmacueticals from a “neutral” rating to a “buy” rating and set a $24.00 target price on the stock in a report on Tuesday, August 9th. Finally, Zacks Investment Research upgraded Bellicum Pharmacueticals from a “sell” rating to a “hold” rating in a report on Monday, July 11th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $27.00.

The firm has a 50-day moving average price of $16.87 and a 200 day moving average price of $12.37. The firm’s market cap is $466.31 million.

Bellicum Pharmacueticals (NASDAQ:BLCM) last released its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.57) by $0.04. During the same quarter in the prior year, the company earned ($0.40) earnings per share. On average, equities research analysts expect that Bellicum Pharmacueticals Inc. will post ($2.34) earnings per share for the current year.

In other news, CTO Kevin M. Slawin sold 2,719 shares of Bellicum Pharmacueticals stock in a transaction that occurred on Monday, July 18th. The stock was sold at an average price of $13.99, for a total transaction of $38,038.81. Following the sale, the chief technology officer now owns 134,206 shares of the company’s stock, valued at $1,877,541.94. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Kevin M. Slawin sold 67,000 shares of Bellicum Pharmacueticals stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $19.31, for a total value of $1,293,770.00. Following the sale, the insider now directly owns 100,079 shares in the company, valued at approximately $1,932,525.49. The disclosure for this sale can be found here.

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.